Drug intelligence / Profile preview

PB220

Development stage
Unknown
Lead developer
Proteos Biotech
Modality
Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration
Subcutaneous, Intradermal
01

Overview

PB220 is a recombinant enzyme product developed by Proteos Biotech, consisting of Collagenase G and Collagenase H derived from *Clostridium histolyticum*. Produced via recombinant DNA technology in bacterial systems, it functions as a proteolytic enzyme that specifically targets and degrades non-functional or amorphous collagen fibers within the extracellular matrix. This mechanism facilitates the remodeling of connective tissue, making it effective for treating pathological collagen accumulation in scars, post-surgical fibrosis, and striae (stretch marks). Marketed under the PBSerum brand, it is also utilized in aesthetic medicine for facial, periocular, and hand rejuvenation to improve skin health and texture. The enzyme is typically provided in a lyophilized form to maintain stability and activity without the need for preservatives.

Brand names
PBSerum
Other names
Collagenase G/HCollagenases G&HRecombinant Collagenase G/HCollagenase G/H PB220

Beyond the preview

Go deeper on PB220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB220.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call